COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials
We did not find any significant unfavourable interaction between regorafenib and patients' co-medications, from any pharmacological class (e.g. anti-acid), either in terms of efficacy or regarding the occurrence of adverse events. These results are reassuring for the safety of regorafenib administered in association with co-medications.
Authors
- Loïc Lebellec (ORCID: https://orcid.org/0000-0002-6079-0185)
- Marie‐Cécile Le Deley (ORCID: https://orcid.org/0000-0002-2946-4592)
- Jean‐Yves Blay (ORCID: https://orcid.org/0000-0001-7190-120X)
- Sylvie Chabaud (ORCID: https://orcid.org/0000-0003-4655-6867)
- Camille Schiffler (ORCID: https://orcid.org/0000-0003-0633-8988)
- Nicolas Penel (ORCID: https://orcid.org/0000-0001-5243-1548)
- Marie Vanseymortier
- Antoine De Courreges
- Frédéric Feutry
- Florence Duffaud (ORCID: https://orcid.org/0000-0002-2057-3557)
- Marta Jimenez (ORCID: https://orcid.org/0000-0002-4233-8478)
- Severine Risbourg
- F Rethouze
Institutions
- Aix-Marseille Université (FR)
- Centre Léon Bérard (FR)
- Centre Oscar Lambret (FR)
- UniCancer Group (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105117
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Bayer HealthCare
- Eisai
- Ligue Contre le Cancer
- Astellas Pharma
- Institut National Du Cancer
- PharmaMar
- Unicancer
- National Cancer Institute